Actively Recruiting
Open-label Study of Surufatinib and Serplulimab Combined with PlatinumEtoposide Chemotherapy in Adults with Neuroendocrine Carcinoma
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-07-14
60
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of surufatinib and serplulimab with standard chemotherapy PlatinumEtoposide in patients with neuroendocrine carcinoma who have not received prior systemic treatment. This open-label, single-arm clinical study aims to assess the safety and effectiveness of this treatment approach in adults with this type of cancer. The trial is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology and includes patients confirmed by pathology with measurable disease and adequate organ function. Participants receive surufatinib orally once daily with dose adjustments based on safety and serplulimab given as an intravenous infusion of 300 mg every three weeks. The chemotherapy regimen includes platinum and etoposide drugs combined with these investigational agents. The treatment is administered according to a defined schedule over several cycles, with doses and timing determined in early safety lead-in phases and subsequent dose expansion. Throughout the study, participants undergo regular monitoring including physical exams, laboratory tests to evaluate organ function, tumor assessments to measure disease progression, and safety evaluations. The main outcome measured is progression-free survival over up to seven years. Participants are followed closely to assess treatment effects, side effects, and overall health status through scheduled visits and assessments during and after treatment.
CONDITIONS
Brief Title
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Research Team
T
Tao Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here